Related Experiment Video
Updated: Jun 27, 2025
A High-throughput Shigella-specific Bactericidal Assay
Published on: February 27, 2019
Shigella Vaccines: The Continuing Unmet Challenge
Ti Lu1, Sayan Das2, Debaki R Howlader1
1Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO 65201, USA.
Insights
Shigellosis poses a global health threat, especially to children. This review examines Shigella vaccine candidates, including whole-cell, live attenuated, LPS-based, and subunit types, to combat this disease.
Area of Science:
- * Infectious Diseases
- * Vaccinology
- * Microbiology
Background:
- * Shigellosis, a severe gastrointestinal illness, affects millions globally, with high mortality in low-income regions and significant impact on young children.
- * Antibiotic resistance exacerbates the public health concern of shigellosis, necessitating novel prevention strategies.
- * The disease causes malnutrition and impaired growth, particularly in children aged 2-5 years.
Purpose of the Study:
- * To review the current status of Shigella vaccine candidates.
- * To explore potential Shigella immunogens and innovative vaccine development approaches.
- * To identify challenges in advancing effective Shigella prevention and control.
Main Methods:
- * Comprehensive literature review of Shigella pathology and vaccine research.
- * Analysis of various vaccine strategies: killed whole-cells, live attenuated, LPS-based, and subunit vaccines.
- * Evaluation of immunogens (LPS, T3SS proteins, outer membrane proteins) and animal models in vaccine development.
Main Results:
- * Multiple Shigella vaccine candidates are under investigation, each with distinct advantages and limitations.
- * Research explores diverse immunogens and utilizes various animal models to assess vaccine efficacy.
- * Innovative approaches are being developed to overcome existing hurdles in Shigella vaccine research.
Conclusions:
- * Developing effective Shigella vaccines is crucial for global public health, particularly in vulnerable populations.
- * Addressing antibiotic resistance and improving vaccine efficacy remain key challenges.
- * Continued research into novel immunogens and vaccine platforms is essential for controlling shigellosis.
Abstract:
Shigellosis is a severe gastrointestinal disease that annually affects approximately 270 million individuals globally. It has particularly high morbidity and mortality in low-income regions; however, it is not confined to these regions and occurs in high-income nations when conditions allow. The ill effects of shigellosis are at their highest in children ages 2 to 5, with survivors often exhibiting impaired growth due to infection-induced malnutrition. The escalating threat of antibiotic resistance further amplifies shigellosis as a serious public health concern. This review explores Shigella pathology, with a primary focus on the status of Shigella vaccine candidates. These candidates include killed whole-cells, live attenuated organisms, LPS-based, and subunit vaccines. The strengths and weaknesses of each vaccination strategy are considered. The discussion includes potential Shigella immunogens, such as LPS, conserved T3SS proteins, outer membrane proteins, diverse animal models used in Shigella vaccine research, and innovative vaccine development approaches. Additionally, this review addresses ongoing challenges that necessitate action toward advancing effective Shigella prevention and control measures.
